Steven Cohen's APGE Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 54,559 shares of Apogee Therapeutics, Inc. (APGE) worth $7.24 M, representing 0.01% of the portfolio. First purchased in 2023-Q3, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Steven Cohen has maintained a strategic position in APGE, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 837,889 shares. Largest reduction occurred in Q3 2025, reducing 1.23 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Apogee Therapeutics (APGE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Apogee Therapeutics (APGE) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +54,559 | New Buy | 54,559 | $132.73 |
| Q3 2025 | -1.23 M | Sold Out | 0 | $0.00 |
| Q2 2025 | +837,889 | Add 213.48% | 1.23 M | $43.43 |
| Q1 2025 | +89,753 | Add 29.65% | 392,488 | $37.36 |
| Q4 2024 | -404,533 | Reduce 57.20% | 302,735 | $45.30 |
| Q3 2024 | +438,036 | Add 162.70% | 707,268 | $58.74 |
| Q2 2024 | -217,968 | Reduce 44.74% | 269,232 | $39.35 |
| Q1 2024 | -221,200 | Reduce 31.23% | 487,200 | $66.45 |
| Q4 2023 | +335,292 | Add 89.86% | 708,400 | $27.94 |
| Q3 2023 | +373,108 | New Buy | 373,108 | $21.30 |
Steven Cohen's Apogee Therapeutics Investment FAQs
Steven Cohen first purchased Apogee Therapeutics, Inc. (APGE) in Q3 2023, acquiring 373,108 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Apogee Therapeutics, Inc. (APGE) for 10 quarters since Q3 2023.
Steven Cohen's largest addition to Apogee Therapeutics, Inc. (APGE) was in Q2 2025, adding 1,230,377 shares worth $53.44 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 54,559 shares of Apogee Therapeutics, Inc. (APGE), valued at approximately $7.24 M.
As of the Q2 2026 filing, Apogee Therapeutics, Inc. (APGE) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Apogee Therapeutics, Inc. (APGE) was 1,230,377 shares, as reported at the end of Q2 2025.